• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Writing dosage of Piperacillin Tazobactam in susceptibility reports: An idea worth trying ??

作者信息

Hada Vivek, Singh Parul, Mohanty Aroop

机构信息

Department of Microbiology, All India Institute of Medical Sciences, Gorakhpur, India.

Department of Microbiology, All India Institute of Medical Sciences, Gorakhpur, India.

出版信息

Indian J Med Microbiol. 2023 Mar-Apr;42:110-111. doi: 10.1016/j.ijmmb.2022.09.003. Epub 2022 Sep 26.

DOI:10.1016/j.ijmmb.2022.09.003
PMID:36175196
Abstract
摘要

相似文献

1
Writing dosage of Piperacillin Tazobactam in susceptibility reports: An idea worth trying ??在药敏报告中书写哌拉西林他唑巴坦的剂量:一个值得尝试的想法??
Indian J Med Microbiol. 2023 Mar-Apr;42:110-111. doi: 10.1016/j.ijmmb.2022.09.003. Epub 2022 Sep 26.
2
In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.鲍曼不动杆菌对比阿培南、哌拉西林/他唑巴坦及其他13种抗菌药物的体外敏感性
Eur J Clin Microbiol Infect Dis. 1994 Jun;13(6):521-3. doi: 10.1007/BF01974651.
3
Clinical implications of revised piperacillin-tazobactam breakpoints in CLSI M-100 S32.CLSI M-100 S32中修订后的哌拉西林-他唑巴坦折点的临床意义
Indian J Med Microbiol. 2023 Mar-Apr;42:108-109. doi: 10.1016/j.ijmmb.2022.09.013. Epub 2022 Oct 11.
4
Letter responding to performance of updated piperacillin-tazobactam breakpoints on the MicroScan antimicrobial susceptibility testing system.关于更新后的哌拉西林-他唑巴坦药敏断点在MicroScan抗菌药物敏感性检测系统上性能表现的回复函
J Clin Microbiol. 2023 Nov 21;61(11):e0049723. doi: 10.1128/jcm.00497-23. Epub 2023 Oct 12.
5
In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species.体外和体内证据不支持对伊丽莎白菌属进行哌拉西林/他唑巴坦药敏的常规检测和报告。
J Antimicrob Chemother. 2024 Jan 3;79(1):200-202. doi: 10.1093/jac/dkad322.
6
Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.比较四种抗菌药物敏感性试验方法以确定哌拉西林和哌拉西林-他唑巴坦对肠杆菌科细菌和铜绿假单胞菌临床分离株的体外活性。
J Clin Microbiol. 2003 Jul;41(7):3339-43. doi: 10.1128/JCM.41.7.3339-3343.2003.
7
Lessons learned from an external quality assurance program in applying CLSI interpretive criteria for reporting piperacillin/tazobactam susceptibility.从应用 CLSI 解释标准报告哌拉西林/他唑巴坦药敏性的外部质量保证计划中吸取的经验教训。
Indian J Med Microbiol. 2024 Mar-Apr;48:100552. doi: 10.1016/j.ijmmb.2024.100552. Epub 2024 Mar 9.
8
The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.厌氧菌临床分离株对哌拉西林-他唑巴坦及其他抗菌药物的敏感性。
J Antimicrob Chemother. 1994 Sep;34(3):415-9. doi: 10.1093/jac/34.3.415.
9
Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.哌拉西林、哌拉西林-舒巴坦和哌拉西林-他唑巴坦对从重症监护患者中分离出的医院病原体的体外活性比较。
Clin Microbiol Infect. 2003 Nov;9(11):1128-32. doi: 10.1046/j.1469-0691.2003.00786.x.
10
Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa.解析2023年临床和实验室标准协会修订的哌拉西林-他唑巴坦对铜绿假单胞菌的折点
Clin Infect Dis. 2023 May 24;76(10):1868-1870. doi: 10.1093/cid/ciad012.